Moderna (MRNA +6%) jumps out the gate this morning on the heels of bullish comments from CEO Stephane Bancel on CNBC’s Mad Money with Jim Cramer pertaining to the company’s personalized cancer vaccines.
CMV vaccine candidate, mRNA-1647, poised to advance into Phase 3 development.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.